Table 1.
Demographics and Baseline characteristics of study population.
| Control | Living Donor | Transplant | CKD | Conventional HD | NIPD | Short Daily HHD | Intermittent Conventional HHD | Frequent Nocturnal HHD | Intermittent Nocturnal HHD | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number | 10 | 10 | 10 | 20 | 10 | 10 | 6 | 5 | 5 | 5 |
| Age (years) | 34 (28–53) | 48 (38–52) | 55 (43–66) | 69 (45–82)* | 64 (62–77)* | 65 (56–76)* | 58 (52–67) | 61 (45–69) | 56 (40–60) | 40 (30–54) |
| Body Mass Index (kg/m2) | 27.1 (5.3) | 25.5 (3.6) | 27.2 (4.1) | 25.6 (3.8) | 28.9 (5.2) | 26.3 (5.3) | 32.8 (6) | 33.7 (11) | 32 (8.8) | 24.8 (3.1) |
| Sex (M/F) | 3/7 | 3/7 | 4/6 | 10/10 | 6/4 | 6/4 | 5/1 | 2/3 | 3/2 | 2/3 |
| Race (C/B/A/F/O) | (10/0/0/0/0) | (9/1/0/0/0) | (10/0/0/0/0) | (19/1/0/0/0) | (10/0/0/0/0) | (8/0/1/1/0) | (6/0/0/0/0) | (4/1/0/0/0) | (5/0/0/0/0) | (4/0/0/0/1) |
| Etiology (DM/PG/SG/IN/H/CHC/M)A | (1/5/1/1/0/0/2) | (4/1/3/0/5/2/5) | (5/1/0/0/2/0/2) | (2/0/1/0/1/0/6) | (2/0/0/0/1/3/0) | (2/1/1/0/0/1/0) | (1/2/0/0/0/1/0/1) | (0/2/0/0/1/2/0) | ||
| Diabetes (N/Y) | 10/0 | 10/0 | 8/2 | 15/5 | 14/6 | 7/3 | 4/2 | 3/2 | 4/1 | 5/0 |
| eGFR (mL/min/1.73 m2) (RV → 1YR)B | 93.5 (78.5–98.25) → 89 (76.75–98.75) | 85.5 (69.25–91.75) → 61.5 (55.25–67.75)† | 68.03 (56.19–74.33) | 12.51 (7.85–18.86)* | 6.385 (4.54–9.13)* | |||||
| Serum Cr (μmol/L) (RV → 1YR)B | 73 (60.75–85) → 71 (65.25–90.5) | 74 (67–82.5) → 99.5 (86–115)† | 97.5 (77.75–109.5) | 361 (281.3–503.8)* | 560.5 (425.3–807)* | 683.5 (537–969.3)* | 832.5 (571.8–863.3)* | 521 (431–698.5)* | 596 (398.5–758.5)* | 596 (495.5–758.5)* |
| Serum Hb (g/L) (RV → 1YR)B | 136.4 (14.29) → 140.7 (12.6) | 131.9 (11.82) → 131.8 (11.08) | 133.5 (21.04) | 113.9 (15.72) | 104 (14.92)* | 105 (11.3)* | 125 (19.91) | 108.8 (23.15) | 105.8 (13.52) | 123.8 (14.67) |
| HD or PD Frequency (sessions/wk) | 3 (3–3) | 6 (5.5–7) | 6 (4.5–6) | 3 (3–4) | 5 (5–6) | 3 (3–3.5) | ||||
| HD or PD weekly duration (min/week) | 630 (608–720) | 2880 (2880–3068)D | 975 (680–1125)DE | 720 (585–840)DE | 2400 (2130–2460)D | 1440 (1260–1750) | ||||
| Kt/V (single pooled for HD, weekly for NIPD) | 1.52 (1.25–1.62) | 1.9 (1.81–2.26) | 1.36 (1.19–1.72) | 1.52 (1.2–2.02) | 2.22 (1.92–2.97)DF | 2.15 (1.8–2.93)D | ||||
| Hemodialysis Membrane Surface Area (m2)C | 1.5 (1.5–1.5) | 1.8 (1.5–2.2) | 1.5 (1.5–1.8) | 1.5 (1.2–1.5) | 1.5 (1.5–1.8) | |||||
| Hemodialysis Qb (blood flow rate) (mL/min) | 350 (350–381) | 400 (375–425) | 400 (400–500) | 300 (225–350) | 300 (250–350) | |||||
| Hemodialysis Qd (dialysate flow rate) (mL/min) | 500 (500–500) | 500 (500–550) | 500 (500–750) | 300 (300–400) | 500 (300–500) |
Demographic characteristics are presented as mean (SD) or median (interquartile range). Statistical differences were determined using the Kruskal-Wallis test followed by Dunn’s Test.
Age and body mass index for Control and Living Donor groups were obtained at recruitment visit (RV).
*p < 0.05 compared to control.
†p < 0.05 by paired analysis.
ADM = diabetes mellitus, PG = primary glomerulonephritis, SG = secondary glomerulonephritis, IN = interstitial nephritis, H = hypertension, CHC = cystic/hereditary/congenital, M = miscellaneous.
BRV measurements are at recruitment visit for Control and prior to kidney donation for Living Donor patients. 1YR measurements were obtained at 1 year follow-up. The arrows signify the separation of values obtained at RV and 1YR.
CMembrane surface area is presented as median (minimum to maximum).
Dp < 0.05 compared to conventional HD.
Ep < 0.05 compared to NIPD.
Fp < 0.05 compared to Home HD SHD.